Biovie Inc logo

Biovie Inc(BIVI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.13
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BIVI

11/13/2026: BIVI (1-star) is currently NOT-A-BUY. Pass it for now.

BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug therapies for neurodegenerative disorders and advanced liver diseases. Its core strengths lie in promising late-stage pipeline candidates like bezisterim and BIV201, which target areas of high unmet medical need. The primary investment story centers on potential clinical breakthroughs and regulatory approvals that could unlock massive market opportunities in neurology and metabolic care. However, the company faces severe financial risks, including zero commercial revenues, ongoing operational cash burn, and high execution risk typical of clinical-stage biotechnology stocks. BioVie best suits speculative growth investors comfortable with high volatility, while key developments to monitor include upcoming clinical data readouts and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the addressable market for its clinical pipeline is vast, revenue growth is absent pending successful drug commercialization.
Momentum investorStrong fit while signal remains positiveShort-term momentum can spike dramatically around clinical data readouts, regulatory updates, or financing announcements.
Value investorWeak fitThe lack of earnings, revenues, and traditional valuation metrics makes fundamental value investing inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital for clinical research.
Low-risk investorWeak fitHigh clinical trial uncertainty, micro-cap volatility, and dilution risk present severe risks for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical-stage shares frequently experience sharp price swings driven by sentiment, trial updates, and capital raises.
Valuation riskMedium / highValuation is purely speculative, tethered to clinical probability of success rather than current sales or profits.
Competition risk (large pharmaceutical therapy competition)HighWell-funded competitors dominate neurodegenerative and liver disease research spaces with superior resources.
Business qualityLowThe absence of commercialized products or established cash flows reflects the typical early-stage biotech risk profile.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighThe company's survival depends on successful clinical trial execution, regulatory compliance, and timely funding.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 12.12M USD
Price to earnings Ratio -
1Y Target Price 5.25
Price to earnings Ratio -
1Y Target Price 5.25
Volume (30-day avg) 662.6K shares
Beta 0.8
52 Weeks Range 0.82 - 3.79
Updated Date 11/15/2026
52 Weeks Range 0.82 - 3.79
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.85

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -65.58%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BIVI receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
BIVI has soft overall fundamentals (2 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-25.8%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
BIVI's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
BIVI's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2026 versus FY2025. By comparison, while earnings growth (-25.8%, negative) and free-cash-flow growth (-99897.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.0% (soft) and 99.5% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.46%, which materially reduces the ownership score.

Top 5 Institutional Investors

Morgan Stanley - Brokerage Accounts 6.97%
Diametric Capital, LP 2.96%
Citadel Advisors Llc 1.11%
Acadian Asset Management LLC 0.93%
Vanguard Capital Management, LLC 0.82%

Unit Economics (Per $1K Revenue)

★★★★★
BIVI generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
BIVI has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development & Future CommercializationInvestigational therapeutics including bezisterim and BIV201 targeted at neurological disorders and liver disease.The company currently makes no commercial money and relies entirely on external financing while it attempts to advance drugs through clinical trials.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4.64M
Price to Sales(TTM) -
Enterprise Value 4.64M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -11.66
Shares Outstanding 10.72M
Shares Floating 10.67M
Shares Outstanding 10.72M
Shares Floating 10.67M
Percent Insiders 0.46
Percent Institutions 19.97

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.